Immupharma Regulatory News (IMM)

21 DECEMBER 2017

ImmuPharma PLC

("ImmuPharma" or the "Company")

Last patient completes dosing in Lupuzor™ Pivotal Phase III Study

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

Study summary as at 21 December 2017

· 200 patients successfully recruited and randomised (dosed)

· Last patient successfully completed dosing

· Continued robust safety record which remains consistent with Lupuzor™'s product profile as shown in its previous Phase IIb study

· Top line results remain on track to be reported in Q1 2018

Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma said: "We are delighted to announce this significant milestone that all patients have now completed dosing in this pivotal Phase III trial for Lupuzor™. Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.